Literature DB >> 21436356

Exercise capacity, muscle strength and fatigue in sarcoidosis.

R G J Marcellis1, A F Lenssen, M D P Elfferich, J De Vries, S Kassim, K Foerster, M Drent.   

Abstract

The aim of this case-control study was to investigate the prevalence of exercise intolerance, muscle weakness and fatigue in sarcoidosis patients. Additionally, we evaluated whether fatigue can be explained by exercise capacity, muscle strength or other clinical characteristics (lung function tests, radiographic stages, prednisone usage and inflammatory markers). 124 sarcoidosis patients (80 males) referred to the Maastricht University Medical Centre (Maastricht, the Netherlands) were included (mean age 46.6±10.2 yrs). Patients performed a 6-min walk test (6MWT) and handgrip force (HGF), elbow flexor muscle strength (EFMS), quadriceps peak torque (QPT) and hamstring peak torque (HPT) tests. Maximal inspiratory pressure (P(I,max)) was recorded. All patients completed the Fatigue Assessment Scale (FAS) questionnaire. The 6MWT was reduced in 45% of the population, while HGF, EFMS, QPT and HPT muscle strength were reduced in 15, 12, 27 and 18%, respectively. P(I,max) was reduced in 43% of the population. The majority of the patients (81%) reported fatigue (FAS ≥22). Patients with reduced peripheral muscle strength of the upper and/or lower extremities were more fatigued and demonstrated impaired lung functions, fat-free mass, P(I,max), 6MWT and quality of life. Fatigue was neither predicted by exercise capacity, nor by muscle strength. Besides fatigue, exercise intolerance and muscle weakness are frequent problems in sarcoidosis. We therefore recommend physical tests in the multidisciplinary management of sarcoidosis patients, even in nonfatigued patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21436356     DOI: 10.1183/09031936.00117710

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  27 in total

Review 1.  Disease Burden and Variability in Sarcoidosis.

Authors:  Alicia K Gerke; Marc A Judson; Yvette C Cozier; Daniel A Culver; Laura L Koth
Journal:  Ann Am Thorac Soc       Date:  2017-12

Review 2.  Patient reported outcome measures (PROMs) in sarcoidosis.

Authors:  Rikke Flor Thunold; Anders Løkke; Adam Langballe Cohen; Hilberg Ole; Elisabeth Bendstrup
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

3.  Physical Activity and Fatigue in Patients with Sarcoidosis.

Authors:  Thomas Bahmer; Henrik Watz; Maria Develaska; Benjamin Waschki; Klaus F Rabe; Helgo Magnussen; Detlef Kirsten; Anne-Marie Kirsten
Journal:  Respiration       Date:  2017-11-09       Impact factor: 3.580

Review 4.  Morbidity and mortality in sarcoidosis.

Authors:  Alicia K Gerke
Journal:  Curr Opin Pulm Med       Date:  2014-09       Impact factor: 3.155

5.  Quality of Life of Couples Living with Sarcoidosis.

Authors:  Mareye Voortman; Celine M R Hendriks; Paul Lodder; Marjolein Drent; Jolanda De Vries
Journal:  Respiration       Date:  2019-08-22       Impact factor: 3.580

6.  Benefits of Physical Training in Sarcoidosis.

Authors:  Bert Strookappe; Jeff Swigris; Jolanda De Vries; Marjon Elfferich; Ton Knevel; Marjolein Drent
Journal:  Lung       Date:  2015-08-19       Impact factor: 2.584

7.  Exercise capacity, muscle strength, and fatigue in sarcoidosis: a follow-up study.

Authors:  Rik G J Marcellis; Antoine F Lenssen; Stephan Kleynen; Jolanda De Vries; Marjolein Drent
Journal:  Lung       Date:  2013-04-05       Impact factor: 2.584

8.  ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.

Authors:  Albert Dahan; Ann Dunne; Maarten Swartjes; Paolo L Proto; Lara Heij; Oscar Vogels; Monique van Velzen; Elise Sarton; Marieke Niesters; Martijn R Tannemaat; Anthony Cerami; Michael Brines
Journal:  Mol Med       Date:  2013-11-08       Impact factor: 6.354

9.  Is there an added value of cardiopulmonary exercise testing in sarcoidosis patients?

Authors:  Rik G J Marcellis; Antoine F Lenssen; Geeuwke J de Vries; Robert P Baughman; Chris P van der Grinten; Johny A Verschakelen; Jolanda De Vries; Marjolein Drent
Journal:  Lung       Date:  2012-11-09       Impact factor: 2.584

10.  Everyday cognitive failure in patients suffering from neurosarcoidosis.

Authors:  Mareye Voortman; Jolanda De Vries; Celine M R Hendriks; Marjon D P Elfferich; Petal A H M Wijnen; Marjolein Drent
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.